Loading…
← CockpitCompetitor Analysis › GLUE Monte Rosa Therapeutics, Inc.Open in the cockpit ↗

Monte Rosa Therapeutics, Inc.GLUECompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops molecular glue degraders, small molecules that harness the body's protein disposal system to destroy disease proteins.

Momentum laggard 10
Mkt cap
$775M
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$13.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.8%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · USD$9.07
1D0.0%
1W-12.0%
1M-20.2%
3M-38.6%
6M-51.4%
YTD-42.2%
1Y-33.4%
ATR %6.6%
Beta0.78
52w lowhigh64.8% off high

What Monte Rosa Therapeutics does

Develops molecular glue degraders, small molecules that harness the body's protein disposal system to destroy disease proteins.

Income comes from partner payments, up-front fees and milestones from Roche and Novartis, plus share sales, which fund its own development; it has no product to sell yet. The platform finds small molecules that make a cell break down a target protein, and the plan is to partner some programs while advancing others itself, notably in autoimmune disease.

Products and services

  • MRT-6160 (VAV1 degrader, autoimmune)
  • Oncology degrader pipeline (partnered with Roche, Novartis)

Customers

  • Pharma partners including Roche and Novartis

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Molecular glue targeted protein…

What could go right

  • Partnership milestone payments from Roche and Novartis
  • Platform-driven pipeline expansion

What could go wrong

  • Clinical trial failure risk
  • Competitive protein-degradation field

Moat: narrow (IP / patents, process know-how). Proprietary discovery platform for molecular glue degraders, validated by major pharma partnerships.

Headquarters: Boston, Massachusetts, US · Founded: 2018 · Employees: 150

Named competitors

Monte Rosa Therapeutics at a glance

Size Monte Rosa Therapeutics (GLUE) is a United States Health Care company (Biotechnology) with a market value of $775M, the 2390th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.07 on 18 Nov 2026.

Performance Over six months the shares fell 51.4%, against -12.2% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 19 in its peer set.

Growth Revenue fell 61.3% over the last twelve months (peer median +15.1%); the operating margin is -214.5% (peer median -84.7%).

Valuation It trades at 3.3× enterprise value to sales against a peer median of 6.8× (4th cheapest of 17).

Short interest Short interest is 24.4% of the free float (30 Oct 2026).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 89GLUE 48
Six months, rebased to 100: Monte Rosa Therapeutics against the median of its 20 peers (local-currency closes).

Monte Rosa Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$70.3M$124M$75.6M$0$0
Revenue growth—+64%———
Gross profit$62.2M$115M$67.5M-$6.22M-$8.56M
EBITDA-$143M-$45.9M-$73.0M-$137M-$104M
Net income-$131M-$38.6M-$72.7M-$135M-$109M
Free cash flow-$174M-$27.5M$38.0M-$62.8M-$105M
Capital expenditure$8.92M$4.70M$3.99M$19.0M$12.9M
Total debt$36.3M$39.2M$42.7M$46.0M$47.0M

Quarterly statements and history in the cockpit →

Monte Rosa Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-25%0%+25%+50%SNDX6885269887IVAAURAMGTXATTO458730152077299966GLUE6-month return →1-month return →
Up and to the right = strong over both horizons. Monte Rosa Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×5,000×10,000×SNDX688526IVAMGTX002038APMDVSTMGLUERevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Monte Rosa Therapeutics is the large dot.

Monte Rosa Therapeutics competitors and peer comparison

Head to head with its named competitors (GLUE vs ARVN vs NRIX vs KYMR)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Monte Rosa Therapeutics GLUE$775M-51%-61%-214%3.3×n/a
Arvinas ARVN$443M-26%-12%-10%n/an/a
Nurix Therapeutics NRIX$1.54B-14%+739%41%0.8×n/a
Kymera Therapeutics KYMR$10.3B+50%+134%-396%92.4×n/a

How Monte Rosa Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Monte Rosa Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureGLUEPeer medianRank in peer set
1-month return-20.2%-6.2%6th lowest of 21
6-month return-51.4%-12.2%2nd lowest of 19
Distance from 52-week high-64.8%-44.9%3rd lowest of 21
Revenue growth (TTM)-61.3%+15.1%2nd lowest of 15
Operating margin-214.5%-84.7%5th lowest of 17
EV / Sales3.3×6.8×4th cheapest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a

Questions

Who are Monte Rosa Therapeutics's main competitors?
Named competitors: Arvinas (ARVN), Nurix Therapeutics (NRIX), Kymera Therapeutics (KYMR). The cockpit's measured peer set (industry) also includes Syndax Pharmaceuticals (SNDX), Wuhan Keqian Biology (688526.SS), Nanjing Leads Biolabs (9887.HK), Inventiva (IVA.PA), Aura Biosciences (AURA), MeiraGTx (MGTX).
Is Monte Rosa Therapeutics expensive compared with its peers?
On ev / sales it trades at 3.3× against a peer median of 6.8×, 4th cheapest of 17 in its peer set.
How has Monte Rosa Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -51.4% against -12.2% for the median peer; over one year -33.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.